Who are The DR group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Edarbi, Cozaar, Lenvatinib + losartan, Candesartan cilexetil/Amlodipine besylate, captopril, Losartan (drug), Valsartan+/- Hydrochlorothiazide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/the-dr-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

The DR group — Competitive Intelligence Brief

The DR group (The DR group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin receptor blocker (ARB). Area: Cardiovascular.

marketed Angiotensin receptor blocker (ARB) AT1 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

The DR group (The DR group) — Beijing Tiantan Hospital. The DR group is a class of drugs that targets the renin-angiotensin system to lower blood pressure and reduce the risk of cardiovascular events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
The DR group TARGET	The DR group	Beijing Tiantan Hospital	marketed	Angiotensin receptor blocker (ARB)	AT1 receptor
Edarbi	AZILSARTAN MEDOXOMIL	Arbor Pharms Ireland	marketed	Angiotensin 2 Receptor Blocker	AT1 receptor	2011-01-01
Cozaar	losartan	Merck & Co.	marketed	ARB (Angiotensin II receptor blocker)	AT1 receptor	1995-04-14
Lenvatinib + losartan	Lenvatinib + losartan	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist	FGFR, VEGFR, RET (lenvatinib); AT1 receptor (losartan)
Candesartan cilexetil/Amlodipine besylate	Candesartan cilexetil/Amlodipine besylate	HK inno.N Corporation	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) / L-type voltage-gated calcium channel
captopril, Losartan (drug)	captopril, Losartan (drug)	National Taiwan University Hospital	marketed	ACE inhibitor and angiotensin II receptor antagonist combination	ACE enzyme and AT1 receptor
Valsartan+/- Hydrochlorothiazide	Valsartan+/- Hydrochlorothiazide	Novartis	marketed	Angiotensin II receptor blocker (ARB); combination with thiazide diuretic when applicable	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (thiazide component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-26 — Edarbi · 9066936 · US
2030-02-04 — Edarbi · 9169238 · US
2031-07-01 — Edarbi · 9387249 · US

Sponsor landscape (Angiotensin receptor blocker (ARB) class)

Beijing Tiantan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). The DR group — Competitive Intelligence Brief. https://druglandscape.com/ci/the-dr-group. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab